Beam Therapeutics Inc.
risto-cel
sickle cell disease
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for risto-cel in sickle cell disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Updated data from the ongoing BEACON Phase 1/2 trial presented at the 67th American Society of Hematology (ASH) Annual Meeting continue to demonstrate risto-cel’s differentiated profile, including deep resolution of SCD markers, reduced hos”